

Fernando Cabanillas

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/2028711/publications.pdf>

Version: 2024-02-01

189
papers

12,412
citations

38720

50
h-index

25770

108
g-index

191
all docs

191
docs citations

191
times ranked

7978
citing authors

#	ARTICLE	IF	CITATIONS
1	Report of an International Workshop to Standardize Response Criteria for Non-Hodgkin's Lymphomas. <i>Journal of Clinical Oncology</i> , 1999, 17, 1244-1244.	0.8	3,209
2	Randomized Controlled Trial of Yttrium-90 ⁹⁰ -Labeled Ibritumomab Tiuxetan Radioimmunotherapy Versus Rituximab Immunotherapy for Patients With Relapsed or Refractory Low-Grade, Follicular, or Transformed B-Cell Non-Hodgkin's Lymphoma. <i>Journal of Clinical Oncology</i> , 2002, 20, 2453-2463.	0.8	1,069
3	Phase II Study of Proteasome Inhibitor Bortezomib in Relapsed or Refractory B-Cell Non-Hodgkin's Lymphoma. <i>Journal of Clinical Oncology</i> , 2005, 23, 667-675.	0.8	517
4	Chemoimmunotherapy with hyper-CVAD plus rituximab for the treatment of adult Burkitt and Burkitt-type lymphoma or acute lymphoblastic leukemia. <i>Cancer</i> , 2006, 106, 1569-1580.	2.0	503
5	Lenalidomide in combination with rituximab for patients with relapsed or refractory mantle-cell lymphoma: a phase 1/2 clinical trial. <i>Lancet Oncology</i> , The, 2012, 13, 716-723.	5.1	274
6	Frequency of gastrointestinal involvement and its clinical significance in mantle cell lymphoma. <i>Cancer</i> , 2003, 97, 586-591.	2.0	232
7	Outcome with the hyper-CVAD regimens in lymphoblastic lymphoma. <i>Blood</i> , 2004, 104, 1624-1630.	0.6	231
8	Ten-year follow-up after intense chemoimmunotherapy with Rituximab-HyperCVAD alternating with Rituximab-high dose methotrexate/cytarabine (R ² MA) and without stem cell transplantation in patients with untreated aggressive mantle cell lymphoma. <i>British Journal of Haematology</i> , 2010, 150, 200-208.	1.2	213
9	Improvement of Overall and Failure-Free Survival in Stage IV Follicular Lymphoma: 25 Years of Treatment Experience at The University of Texas M.D. Anderson Cancer Center. <i>Journal of Clinical Oncology</i> , 2006, 24, 1582-1589.	0.8	192
10	Long-term results with radiotherapy for stage I-II follicular lymphomas. <i>International Journal of Radiation Oncology Biology Physics</i> , 2001, 51, 1219-1227.	0.4	156
11	The Clinical Significance of Molecular Response in Indolent Follicular Lymphomas. <i>Blood</i> , 1998, 91, 2955-2960.	0.6	145
12	Lymphoma of the nasal cavity and paranasal sinuses. <i>Cancer</i> , 1997, 80, 477-488.	2.0	131
13	In Support of a Patient-Driven Initiative and Petition to Lower the High Price of Cancer Drugs. <i>Mayo Clinic Proceedings</i> , 2015, 90, 996-1000.	1.4	128
14	Radiotherapy during pregnancy for clinical stages IA-IIA Hodgkin's disease. <i>International Journal of Radiation Oncology Biology Physics</i> , 1992, 23, 407-412.	0.4	126
15	Long-Term Follow-Up of a Prospective Study of Combined Modality Therapy for Stage I-II Indolent Non-Hodgkin's Lymphoma. <i>Journal of Clinical Oncology</i> , 2003, 21, 2115-2122.	0.8	122
16	Activity of TNF-related apoptosis-inducing ligand (TRAIL) in haematological malignancies. <i>British Journal of Haematology</i> , 1997, 99, 618-624.	1.2	120
17	Correlation of Bcl-2 Rearrangement With Clinical Characteristics and Outcome in Indolent Follicular Lymphoma. <i>Blood</i> , 1999, 93, 3081-3087.	0.6	118
18	Functional expression of receptor activator of nuclear factor κ B in Hodgkin disease cell lines. <i>Blood</i> , 2001, 98, 2784-2790.	0.6	117

#	ARTICLE	IF	CITATIONS
19	Novel 5' Exonuclease-Based Real-Time PCR Assay for the Detection of t(14;18)(q32;q21) in Patients with Follicular Lymphoma. <i>American Journal of Pathology</i> , 1998, 153, 63-68.	1.9	114
20	Primary Ovarian Non-Hodgkin's Lymphoma: Outcome after Treatment with Combination Chemotherapy. <i>Gynecologic Oncology</i> , 1997, 64, 446-450.	0.6	111
21	Management with chemotherapy only of stage I and II malignant lymphoma of aggressive histologic types. <i>Cancer</i> , 1980, 46, 2356-2359.	2.0	106
22	Localized primary malignant lymphoma of bone. <i>International Journal of Radiation Oncology Biology Physics</i> , 1997, 37, 1087-1093.	0.4	97
23	Human interferon alpha in malignant lymphoma and Hodgkin's disease. Results of the american cancer society trial. <i>Cancer</i> , 1985, 56, 1305-1310.	2.0	95
24	Stage III follicular lymphoma: Treatment results for 76 patients. <i>Cancer</i> , 1986, 58, 1596-1602.	2.0	94
25	Differential Expression of BCL-2 Family Proteins in ALK-Positive and ALK-Negative Anaplastic Large Cell Lymphoma of T/Null-Cell Lineage. <i>American Journal of Pathology</i> , 2001, 159, 527-535.	1.9	90
26	Mantle-cell lymphoma. <i>Lancet Oncology</i> , The, 2001, 2, 141-148.	5.1	90
27	BCL-2 expression in Hodgkin and Reed-Sternberg cells of classical Hodgkin disease predicts a poorer prognosis in patients treated with ABVD or equivalent regimens. <i>Blood</i> , 2002, 100, 3935-3941.	0.6	90
28	Factors Predicting for Response and Survival in Adults With Advanced Non-Hodgkin's Lymphoma. <i>Archives of Internal Medicine</i> , 1978, 138, 413.	4.3	87
29	Phase II study of sphingosomal vincristine in patients with recurrent or refractory adult acute lymphocytic leukemia. <i>Cancer</i> , 2006, 106, 120-127.	2.0	85
30	Rituximab plus hyperfractionated cyclophosphamide alternating with methotrexate and prednisone in patients with newly diagnosed mantle cell lymphoma: 15-year follow-up of a phase II study from the MD Anderson Cancer Center. <i>British Journal of Haematology</i> , 2016, 172, 80-88.	1.2	82
31	Localized Primary Non-Hodgkin Lymphoma of the Breast. <i>American Journal of Clinical Oncology: Cancer Clinical Trials</i> , 1998, 21, 376-380.	0.6	77
32	9'-D-Arabinofuranosyl-2-fluoroadenine 5'-monophosphate pharmacokinetics in plasma and tumor cells of patients with relapsed leukemia and lymphoma. <i>Cancer Chemotherapy and Pharmacology</i> , 1986, 18, 145-52.	1.1	73
33	Refractoriness to chemotherapy and poor survival related to abnormalities of chromosomes 17 and 7 in lymphoma. <i>American Journal of Medicine</i> , 1989, 87, 167-172.	0.6	71
34	Fine-Needle Aspiration Cytology of Peripheral T-Cell Lymphoma: A Cytologic, Immunologic, and Cytometric Study. <i>American Journal of Clinical Pathology</i> , 1989, 91, 120-131.	0.4	71
35	T-Cell-Rich B Large-Cell Lymphoma Simulating Lymphocyte-Rich Hodgkin's Disease. <i>American Journal of Surgical Pathology</i> , 1996, 20, 193-201.	2.1	68
36	Randomized trial of beta-lactam regimens in febrile neutropenic cancer patients. <i>American Journal of Medicine</i> , 1988, 84, 581-589.	0.6	67

#	ARTICLE	IF	CITATIONS
37	European Organization for Research and Treatment of Cancer and Groupe d'Etude des Lymphomes de l'Adulte very favorable and favorable, lymphocyte-predominant Hodgkin disease. <i>Cancer</i> , 2002, 94, 1731-1738.	2.0	67
38	CD30 ligand is expressed on resting normal and malignant human B lymphocytes. <i>British Journal of Haematology</i> , 1996, 93, 569-571.	1.2	66
39	Untreated Aggressive Mantle Cell Lymphoma: Results with Intensive Chemotherapy without Stem Cell Transplant in Elderly Patients. <i>Leukemia and Lymphoma</i> , 2000, 39, 77-85.	0.6	64
40	Radiotherapy Alone for Lymphocyte-Predominant Hodgkin's Disease. <i>Cancer Journal (Sudbury, Mass)</i> , 2002, 8, 377-383.	1.0	64
41	Accuracy of diagnosis of malignant lymphoma by combining fine-needle aspiration cytomorphology with immunocytochemistry and in selected cases, southern blotting of aspirated cells: A tissue-controlled study of 86 patients. <i>Diagnostic Cytopathology</i> , 1992, 8, 456-464.	0.5	63
42	Sequential chemotherapy and late intensification for malignant lymphomas of aggressive histologic type. <i>American Journal of Medicine</i> , 1983, 74, 382-388.	0.6	61
43	COINCIDENT RENAL CELL CARCINOMA AND NONHODGKIN'S LYMPHOMA: THE M.D. ANDERSON EXPERIENCE AND REVIEW OF THE LITERATURE. <i>Journal of Urology</i> , 1998, 159, 714-717.	0.2	61
44	Fludarabine, mitoxantrone, dexamethasone (FND) compared with an alternating triple therapy (ATT) regimen in patients with stage IV indolent lymphoma. <i>Blood</i> , 2002, 100, 4351-4357.	0.6	59
45	Apoptotic Rate in Peripheral T-Cell Lymphomas. <i>American Journal of Clinical Pathology</i> , 2002, 118, 328-334.	0.4	58
46	Hodgkin's Disease Variant of Richter's Syndrome: Experience at a Single Institution. <i>Leukemia and Lymphoma</i> , 1996, 23, 333-337.	0.6	55
47	Chemotherapy as definitive treatment of stage I-II large cell and diffuse mixed lymphomas. <i>Hematological Oncology</i> , 1985, 3, 25-31.	0.8	54
48	The Role of Mitoxantrone in the Treatment of Indolent Lymphomas. <i>Oncologist</i> , 2005, 10, 150-159.	1.9	54
49	Central nervous system prophylaxis with combined intravenous and intrathecal methotrexate in diffuse lymphoma of aggressive histologic type. <i>Cancer</i> , 1986, 57, 971-977.	2.0	52
50	β-Lactam regimens for the febrile neutropenic patient. <i>Cancer</i> , 1990, 65, 9-16.	2.0	51
51	Nodular malignant lymphomas. Factors affecting complete response rate and survival. <i>Cancer</i> , 1979, 44, 1983-1989.	2.0	49
52	LONG-TERM FOLLOW-UP OF PLATINUM-BASED LYMPHOMA SALVAGE REGIMENS. <i>Hematology/Oncology Clinics of North America</i> , 1997, 11, 937-947.	0.9	49
53	Significance of tumor size and radiation dose to local control in Stage III diffuse large cell lymphoma treated with CHOP-Bleo and radiation. <i>International Journal of Radiation Oncology Biology Physics</i> , 1995, 31, 3-11.	0.4	48
54	Coexpression of CD40 and CD40 ligand in B-cell lymphoma cells. <i>British Journal of Haematology</i> , 1998, 103, 270-275.	1.2	47

#	ARTICLE	IF	CITATIONS
55	International prognostic index-based outcomes for diffuse large B-cell lymphomas. <i>Cancer</i> , 2002, 94, 3083-3088.	2.0	47
56	Detection of Chromosome 11q13 Breakpoints by Interphase Fluorescence In Situ Hybridization. <i>American Journal of Clinical Pathology</i> , 2000, 114, 248-257.	0.4	46
57	Chromosomal abnormalities in adult non-endemic burkitt's lymphoma and leukemia: 22 new reports and a review of 148 cases from the literature. <i>Hematological Oncology</i> , 2006, 9, 63-78.	0.8	46
58	Protected environment-prophylactic antibiotic program for malignant lymphoma. <i>American Journal of Medicine</i> , 1979, 66, 74-81.	0.6	44
59	Nephrotoxicity of Combined Cephalothin-Gentamicin Regimen. <i>Archives of Internal Medicine</i> , 1975, 135, 850.	4.3	43
60	Elevated Serum Levels of IL-10 are Associated with Inferior Progression-Free Survival in Patients with Hodgkin's Disease Treated with Radiotherapy. <i>Leukemia and Lymphoma</i> , 2004, 45, 2085-2092.	0.6	43
61	Expression of CD40 ligand (CD154) in B and T lymphocytes of Hodgkin disease. <i>Cancer</i> , 2002, 94, 1-5.	2.0	42
62	Marginal zone lymphomas. <i>Cancer</i> , 2010, 116, 4291-4298.	2.0	42
63	High Serum Interleukin-6 Levels Correlate with a Shorter Failure-Free Survival in Indolent Lymphoma. <i>Leukemia and Lymphoma</i> , 1998, 30, 563-571.	0.6	41
64	Surgical debulking is associated with improved survival in stage I-II diffuse large cell lymphoma. <i>Cancer</i> , 1990, 66, 267-272.	2.0	38
65	High dose therapy and autologous marrow transplantation as salvage treatment for patients with diffuse large cell lymphoma. <i>European Journal of Cancer & Clinical Oncology</i> , 1986, 22, 871-877.	0.9	37
66	An elevated serum beta-2-microglobulin level is an adverse prognostic factor for overall survival in patients with early-stage Hodgkin disease. <i>Cancer</i> , 2002, 95, 2534-2538.	2.0	37
67	Very high levels of soluble CD30 recognize the patients with classical Hodgkin's lymphoma retaining a very poor prognosis. <i>European Journal of Haematology</i> , 2006, 77, 387-394.	1.1	37
68	Paclitaxel activity for the treatment of non-Hodgkin's lymphoma: final report of a phase II trial. <i>British Journal of Haematology</i> , 1997, 96, 328-332.	1.2	34
69	Epigenetic therapy of lymphoma using histone deacetylase inhibitors. <i>Clinical and Translational Oncology</i> , 2010, 12, 401-409.	1.2	33
70	The outcome of combined-modality treatments for stage I and II primary large B-cell lymphoma of the mediastinum. <i>International Journal of Radiation Oncology Biology Physics</i> , 2000, 47, 1281-1285.	0.4	32
71	Thalidomide for patients with recurrent lymphoma. <i>Cancer</i> , 2004, 100, 1186-1189.	2.0	31
72	Phase 2 trial of rituximab plus hyper-CVAD alternating with rituximab plus methotrexate-cytarabine for relapsed or refractory aggressive mantle cell lymphoma. <i>Cancer</i> , 2008, 113, 2734-2741.	2.0	31

#	ARTICLE	IF	CITATIONS
73	Prognostic significance of baseline peripheral absolute neutrophil, monocyte and serum Î²2â€microglobulin level in patients with diffuse large bâ€cell lymphoma: a new prognostic model. British Journal of Haematology, 2016, 175, 290-299.	1.2	31
74	Long-term outcome of treatment for ann arbor Stage 1 Hodgkin's disease: Patterns of failure, late toxicity and second malignancies. International Journal of Radiation Oncology Biology Physics, 1997, 39, 609-616.	0.4	30
75	Apoptotic Induction in Transformed Follicular Lymphoma Cells by Bcl-2 Downregulation. Leukemia and Lymphoma, 1998, 30, 367-380.	0.6	30
76	Analysis of in-field control and late toxicity for adults with early-stage hodgekinâ€™s disease treated with chemotherapy followed by radiotherapy. International Journal of Radiation Oncology Biology Physics, 2003, 55, 36-43.	0.4	30
77	Long term results of a phase 2 study of vincristine sulfate liposome injection (^Marqibo^Â) substituted for nonâ€liposomal vincristine in cyclophosphamide, doxorubicin, vincristine, prednisone with or without rituximab for patients with untreated aggressive nonâ€H</sup>odgkin lymphomas. British Journal of Haematology, 2013, 162, 631-638.	1.2	30
78	Longâ€term outcomes, secondary malignancies and stem cell collection following bendamustine in patients with previously treated nonâ€Hodgkin lymphoma. British Journal of Haematology, 2017, 178, 250-256.	1.2	30
79	Trimetrexate in Relapsed T-Cell Lymphoma With Skin Involvement. Journal of Clinical Oncology, 2002, 20, 2876-2880.	0.8	29
80	Advances in Diagnosis and Management of Diffuse Large B-cell Lymphoma. Clinical Lymphoma, Myeloma and Leukemia, 2017, 17, 783-796.	0.2	29
81	Outcome of Hodgkin's disease in elderly patients. Hematological Oncology, 1995, 13, 19-27.	0.8	28
82	Primary parotid lymphoma: the effect of international prognostic index on outcome. Leukemia and Lymphoma, 1997, 26, 49-56.	0.6	28
83	Second Malignancies After Chemotherapy and Radiotherapy for Hodgkin Disease. American Journal of Clinical Oncology: Cancer Clinical Trials, 2004, 27, 73-80.	0.6	28
84	Primary Non-Hodgkin Lymphoma of the Small Bowel. Radiology, 1999, 211, 183-187.	3.6	27
85	Primary Effusion Lymphoma in an Hiv-Negative Patient with No Serologic Evidence of Kaposi's Sarcoma Virus. Leukemia and Lymphoma, 2001, 41, 185-189.	0.6	27
86	Front-line management of diffuse large B cell lymphoma. Current Opinion in Oncology, 2010, 22, 642-645.	1.1	27
87	A review and interpretation of cytogenetic abnormalities identified in Hodgkin's disease. Hematological Oncology, 1988, 6, 271-274.	0.8	26
88	Primary mediastinal large cell lymphoma. Hematological Oncology, 1994, 12, 175-184.	0.8	26
89	The Expanding Role of Fludarabine in Hematologic Malignancies. Leukemia and Lymphoma, 1994, 14, 11-16.	0.6	26
90	Bulky disease is an adverse prognostic factor in patients treated with chemotherapy comprised of cyclophosphamide, doxorubicin, vincristine, and prednisone with or without radiotherapy for aggressive lymphoma. Cancer, 2001, 91, 2440-2446.	2.0	26

#	ARTICLE	IF	CITATIONS
91	Is there an increased rate of additional malignancies in patients with mantle cell lymphoma?. <i>Annals of Oncology</i> , 2002, 13, 318-322.	0.6	26
92	Prognostic value of serum CD44, intercellular adhesion molecule-1 and vascular cell adhesion molecule-1 levels in patients with indolent non-Hodgkin lymphomas. <i>Leukemia and Lymphoma</i> , 2012, 53, 50-56.	0.6	26
93	The adjuvant role of two cycles of MOPP and low-dose lung irradiation in stage ia through iib hodgkin's disease: Preliminary results. <i>International Journal of Radiation Oncology Biology Physics</i> , 1988, 14, 683-692.	0.4	25
94	Tumor Necrosis Factor- α and Interferon- β , but not HTLV-I Tax, are Likely Factors in the Epidermotropism of Cutaneous T-Cell Lymphoma via Induction of Interferon-Inducible Protein-10. <i>Leukemia and Lymphoma</i> , 1998, 29, 315-328.	0.6	25
95	Human central nervous system pharmacology of pentamethylmelamine and its metabolites. <i>Journal of Neuro-Oncology</i> , 1983, 1, 357-364.	1.4	24
96	Unbalanced expression of Fas and CD40 in mantle cell lymphoma. <i>British Journal of Haematology</i> , 1998, 103, 217-219.	1.2	24
97	Primary central nervous system lymphoma: Phase I evaluation of infusional bromodeoxyuridine with whole brain accelerated fractionation radiation therapy after chemotherapy. <i>Cancer</i> , 2003, 98, 1021-1028.	2.0	23
98	Evaluation of Breast Imaging Reporting and Data System Category 3 mammograms and the use of stereotactic vacuum-assisted breast biopsy in a nonacademic community practice. <i>Cancer</i> , 2004, 100, 710-714.	2.0	23
99	Immunosuppression and infectious complications in patients with stage IV indolent lymphoma treated with a fludarabine, mitoxantrone, and dexamethasone regimen. <i>Cancer</i> , 2005, 104, 345-353.	2.0	23
100	Polysomy of chromosome 12 in 60 patients with non-hodgkin's lymphoma assessed by fluorescence in situ hybridization: Differences between follicular and diffuse large cell lymphoma. <i>Genes Chromosomes and Cancer</i> , 1994, 9, 161-167.	1.5	22
101	Interleukin-13 levels in serum from patients with Hodgkin disease and healthy volunteers. <i>Blood</i> , 2001, 98, 2877-2878.	0.6	22
102	Intensive induction chemotherapy of extensive small cell bronchogenic carcinoma in protected environmentâ€”Prophylactic antibiotic units A preliminary report. <i>International Journal of Radiation Oncology Biology Physics</i> , 1980, 6, 1087-1092.	0.4	21
103	Subdiaphragmatic stage I & II Hodgkinâ€™s disease: long-term follow-up and prognostic factors. <i>International Journal of Radiation Oncology Biology Physics</i> , 1998, 41, 1047-1056.	0.4	21
104	Apoptosis and the BCL-2 gene family - patterns of expression and prognostic value in STAGE I and II follicular center lymphoma. <i>International Journal of Radiation Oncology Biology Physics</i> , 1999, 44, 19-29.	0.4	21
105	Central lymphatic irradiation for stage Iâ€”III follicular lymphoma: report from a single-institutional prospective study. <i>International Journal of Radiation Oncology Biology Physics</i> , 2003, 57, 316-320.	0.4	21
106	Rising Serum Lactate Dehydrogenase Often Caused by Granulocyte-or Granulocyte-Macrophage Colony Stimulating Factor and not Tumor Progression in Patients with Lymphoma or Myeloma. <i>Leukemia and Lymphoma</i> , 1995, 17, 473-477.	0.6	20
107	Hematopoietic Retroviral Gene Marking in Patients with Follicular Non-Hodgkin's Lymphoma. <i>Leukemia and Lymphoma</i> , 1999, 32, 279-288.	0.6	20
108	Mucosa-associated lymphoid tissue lymphoma with initial supradiaphragmatic presentation: natural history and patterns of disease progression. <i>International Journal of Radiation Oncology Biology Physics</i> , 2000, 48, 399-403.	0.4	20

#	ARTICLE	IF	CITATIONS
109	Chromosomal abnormalities in lymphoma and their correlations with nucleic acid flow cytometry. <i>Cancer Genetics and Cytogenetics</i> , 1986, 21, 99-106.	1.0	19
110	Importance of Esophagogastroduodenoscopy in the Evaluation of Non-Gastrointestinal Mucosa-Associated Lymphoid Tissue Lymphoma. <i>Cancer Journal (Sudbury, Mass)</i> , 2003, 9, 321-324.	1.0	19
111	Effects of intensive induction chemotherapy for extensive-disease small cell bronchogenic carcinoma in protected environment-prophylactic antibiotic units. <i>American Journal of Medicine</i> , 1984, 76, 405-412.	0.6	18
112	Risk Classification for Large Cell Lymphoma using Lactate Dehydrogenase, Beta-2 Microglobulin, and Thymidine Kinase. <i>Leukemia and Lymphoma</i> , 1995, 18, 87-92.	0.6	18
113	Ventricular fibrillation following AMSA. Uncomplicated retreatment following correction of hypokalemia. <i>Cancer</i> , 1983, 52, 557-558.	2.0	17
114	Curability of Advanced Indolent or Low-Grade Follicular Lymphomas: Time for a New Paradigm?. <i>Journal of Clinical Oncology</i> , 2013, 31, 14-16.	0.8	17
115	Comparison of lymphangiograms and gallium scans in the non-Hodgkin's lymphomas. <i>Cancer</i> , 1977, 39, 85-88.	2.0	16
116	Analysis of p53 gene deletions in patients with non-Hodgkin's lymphoma by dual-colour fluorescence in situ hybridization. <i>British Journal of Haematology</i> , 1997, 98, 913-921.	1.2	16
117	Mantle irradiation alone for pathologic stage I and II Hodgkin's disease: long-term follow-up and patterns of failure. <i>International Journal of Radiation Oncology Biology Physics</i> , 2001, 50, 971-977.	0.4	15
118	Non-Hodgkin's Lymphoma: The Old and the New. <i>Clinical Lymphoma, Myeloma and Leukemia</i> , 2011, 11, S87-S90.	0.2	15
119	Vitamin C and cancer: what can we conclude—1,609 patients and 33 years later?. <i>Puerto Rico Health Sciences Journal</i> , 2010, 29, 215-7.	0.2	15
120	Quantitative Real-Time Polymerase Chain Reaction for Detection of Circulating Cells with T(14;18) in Volunteer Blood Donors and Patients with Follicular Lymphoma. <i>Leukemia and Lymphoma</i> , 2002, 43, 1589-1598.	0.6	14
121	High ten-year remission rates following rituximab, fludarabine, mitoxantrone and dexamethasone (R-FND) with interferon maintenance in indolent lymphoma: Results of a randomized Study. <i>British Journal of Haematology</i> , 2017, 177, 263-270.	1.2	14
122	Stage III follicular lymphoma: long-term follow-up and patterns of failure. <i>International Journal of Radiation Oncology Biology Physics</i> , 2003, 57, 748-754.	0.4	13
123	Variations in Chemotherapy and Radiation Therapy in a Large Nationwide and Community-Based Cohort of Elderly Patients With Non-Hodgkin Lymphoma. <i>American Journal of Clinical Oncology: Cancer Clinical Trials</i> , 2007, 30, 163-171.	0.6	13
124	Successful Use of Bortezomib-Lenalidomide Combination as Treatment for a Patient With Plasmablastic Lymphoma. <i>Clinical Lymphoma, Myeloma and Leukemia</i> , 2018, 18, e275-e277.	0.2	13
125	16-Year Experience at M. D. Anderson Cancer Center with Primary Ki-1 (CD30) Antigen Expression and Anaplastic Morphology in Adult Patients with Diffuse Large Cell Lymphoma. <i>Leukemia and Lymphoma</i> , 1995, 20, 97-102.	0.6	12
126	Interferon-Inducible Protein-10 and the Pathogenesis of Cutaneous T-Cell Lymphomas. <i>Leukemia and Lymphoma</i> , 1996, 24, 103-110.	0.6	12

#	ARTICLE	IF	CITATIONS
127	Phase I Study of Fludarabine and Paclitaxel for the Treatment of Low-Grade Non-Hodgkin's Lymphoma. Leukemia and Lymphoma, 1997, 26, 77-82.	0.6	12
128	How important is whole brain radiotherapy for treatment of primary CNS lymphoma?. Lancet Oncology, The, 2010, 11, 1011-1012.	5.1	12
129	Phase <sc>II</sc> study of bortezomib in combination with rituximab, cyclophosphamide and prednisone with or without doxorubicin followed by rituximab maintenance in patients with relapsed or refractory follicular lymphoma. British Journal of Haematology, 2014, 166, 920-928.	1.2	12
130	Soluble CD95 in the Serum of Patients with Low and Intermediate Grade Malignant Lymphomas: Absence of Prognostic Correlations. Leukemia and Lymphoma, 1997, 27, 517-521.	0.6	11
131	The significance of molecular response of follicular lymphoma to central lymphatic irradiation as measured by polymerase chain reaction for t(14;18)(q32;q21). International Journal of Radiation Oncology Biology Physics, 2001, 49, 727-732.	0.4	11
132	Outcomes Using Doxorubicin-Based Chemotherapy with or without Radiotherapy for Early-Stage Peripheral T-cell Lymphomas. Leukemia and Lymphoma, 2002, 43, 1769-1775.	0.6	11
133	Effective combination chemotherapy of adult malignant histiocytosis (histiocytic medullary) Tj ETQq1 1 0.784314 rgBT /Overlock 10 Tj ETQq1 1 0.784314 rgBT /Overlock 10	0.6	10
134	Monosomy 21, partial duplication of chromosome 11, and structural abnormality of chromosome 1q21 in a case of lymphoma developing in a transplant recipient: Characteristic abnormalities of secondary lymphoma?. Cancer Genetics and Cytogenetics, 1987, 24, 7-10.	1.0	10
135	Long-term outcome of treatment for ann arbor Stage I Hodgkin's disease: Prognostic factors for survival and freedom from progression. International Journal of Radiation Oncology Biology Physics, 1997, 38, 593-599.	0.4	10
136	Correlation of Bcl-2 Rearrangement With Clinical Characteristics and Outcome in Indolent Follicular Lymphoma. Blood, 1999, 93, 3081-3087.	0.6	10
137	Use of Retroviral Markers to Identify Efficacy of Purging and Origin of Relapse Following Autologous Bone Marrow and Peripheral Blood Cell Transplantation in Indolent B Cell Neoplasms (Follicular) Tj ETQq1 1 0.784314 rgBT /Overlock 10 Tj ETQq1 1 0.784314 rgBT /Overlock 10 Anderson Cancer Center. Human Gene Therapy, 1993, 4, 821-834.	1.4	9
138	High incidence of monosomy 18 in lymphoid malignancies that have bone marrow and peripheral blood involvement. Cancer Genetics and Cytogenetics, 1994, 77, 39-44.	1.0	9
139	Simultaneous presentation of hairy cell leukemia and follicular small cleaved cell lymphoma in a patient with previous diagnosis of renal cell carcinoma. Hematological Oncology, 1995, 13, 63-67.	0.8	9
140	Study of the Natural History of Immunoblastic Lymphadenopathy and Atypical Immunoproliferative Disorders. Cancer Investigation, 1983, 1, 293-299.	0.6	8
141	The hematologic malignancies: Leukemia, lymphoma, and myeloma. Cancer, 1984, 54, 2741-2750.	2.0	8
142	Cisplatin-CBV with Autologous Bone Marrow Transplantation for Relapsed Hodgkin's Disease. Leukemia and Lymphoma, 1993, 9, 71-77.	0.6	8
143	Chromosome X numerical abnormalities in patients with Non-Hodgkin's Lymphoma. Cancer Genetics and Cytogenetics, 1995, 82, 23-29.	1.0	8
144	Paclitaxel plus high-dose cyclophosphamide with G-CSF support in patients with relapsed and refractory aggressive non-Hodgkin's lymphoma. British Journal of Haematology, 1998, 103, 678-683.	1.2	8

#	ARTICLE	IF	CITATIONS
145	Results with chemotherapy comprised of cyclophosphamide, doxorubicin, vincristine, and prednisone followed by radiotherapy with or without prechemotherapy surgical debulking for patients with bulky, aggressive lymphoma. <i>Cancer</i> , 2002, 94, 601-605.	2.0	8
146	Establishment and Characterization of a New Mantle Cell Lymphoma Cell Line M-1. <i>Leukemia and Lymphoma</i> , 2004, 45, 1255-1260.	0.6	8
147	Mantle Cell Lymphoma with t(11;22) (q13;q11.2) an indolent clinical variant?. <i>Leukemia and Lymphoma</i> , 2018, 59, 2509-2511.	0.6	8
148	Improvement in complete response rate, duration of response and survival with adriamycin combination chemotherapy for non-Hodgkin lymphoma: A prognostic factor comparison of two regimens. <i>Medical and Pediatric Oncology</i> , 1978, 4, 321-331.	1.0	7
149	Phase 2 study of fludarabine and paclitaxel in patients with recurrent low-grade non-Hodgkin's lymphoma. <i>Leukemia and Lymphoma</i> , 2006, 47, 1818-1821.	0.6	7
150	Recent advances in the management of mantle cell lymphoma. <i>Current Opinion in Oncology</i> , 2013, 25, 716-721.	1.1	7
151	Indolent Lymphomas That Present With Clinically Aggressive Features: A Subset of Low-Grade Lymphomas With a Behavior Inconsistent With the Histologic Diagnosis. <i>Clinical Lymphoma, Myeloma and Leukemia</i> , 2016, 16, 550-557.	0.2	7
152	Rituximab (R) + Hypercvad Alternating with R-Methotrexate/Cytarabine after 9 Years: Continued High Rate of Failure-Free Survival in Untreated Mantle Cell Lymphoma (MCL). <i>Blood</i> , 2008, 112, 833-833.	0.6	7
153	What Constitutes a "Cure" in Lymphoma?. <i>Leukemia and Lymphoma</i> , 1993, 11, 161-163.	0.6	6
154	A prospective randomized study to compare the molecular response rates between central lymphatic irradiation and intensive alternating triple chemotherapy in the treatment of stage I-III follicular lymphoma. <i>International Journal of Radiation Oncology Biology Physics</i> , 2005, 63, 188-193.	0.4	6
155	Philadelphia chromosome without breakpoint cluster region rearrangement in a case of Lennert's lymphoma of suppressor phenotype. <i>Hematological Oncology</i> , 1989, 7, 189-194.	0.8	5
156	Lymphomatous Presentation of CD4+/CD8+ HTLV-1-Related Adult T-cell Leukemia/Lymphoma in an Iranian Woman. <i>Leukemia and Lymphoma</i> , 1994, 12, 471-476.	0.6	5
157	Phase II study of paclitaxel in combination with mitoxantrone and ifosfamide/mesna for patients with relapsed or refractory non-Hodgkin's lymphoma after failure to cytarabine/cisplatin combination. <i>Investigational New Drugs</i> , 1999, 17, 187-192.	1.2	5
158	Hematologic recovery after central lymphatic irradiation for patients with stage I-III follicular lymphoma. <i>Cancer</i> , 2001, 92, 1074-1079.	2.0	5
159	Primary cutaneous non-Hodgkin's lymphoma with aggressive histology: inferior outcome is associated with peripheral T-cell type and elevated lactate dehydrogenase, but not extent of cutaneous involvement. <i>Annals of Oncology</i> , 2002, 13, 1290-1299.	0.6	5
160	HLA class II antigen associated invariant chain gene expression in malignant lymphoma. <i>British Journal of Haematology</i> , 1987, 67, 413-417.	1.2	4
161	Rituximab in DLBCL: 6 years on. <i>Lancet Oncology</i> , The, 2011, 12, 984-985.	5.1	4
162	Successful Treatment of a Patient With Epstein-Barr Virus "Positive" B-Cell Lymphoproliferative Disorder Resembling Post-Transplant Lymphoproliferative Disorder Using Single-Agent Rituximab. <i>Journal of Clinical Oncology</i> , 2011, 29, e658-e660.	0.8	4

#	ARTICLE	IF	CITATIONS
163	Human B Cell Lymphomas: <i>In Vitro</i> and <i>In Vivo</i> Studies on Growth Factors and Cell Growth. <i>Leukemia and Lymphoma</i> , 1993, 10, 51-56.	0.6	3
164	Endocrine Characterization of Primary Mediastinal Lymphoma. <i>Leukemia and Lymphoma</i> , 1996, 23, 613-615.	0.6	3
165	Therapeutic concepts in mantle cell lymphoma. <i>European Journal of Haematology</i> , 2010, 85, 371-386.	1.1	3
166	Results of Upfront Therapy for Marginal Zone Lymphoma. <i>Clinical Lymphoma, Myeloma and Leukemia</i> , 2017, 17, 879-883.	0.2	3
167	Incidence and Risk Factors for Developing Herpes Zoster Among a Cohort of Patients Diagnosed With Lymphoma at a Community Cancer Center. <i>Clinical Lymphoma, Myeloma and Leukemia</i> , 2019, 19, e153-e158.	0.2	3
168	Evaluation of the MD Anderson tumor score for diffuse large B-cell lymphoma in the rituximab era. <i>European Journal of Haematology</i> , 2020, 104, 400-408.	1.1	3
169	Hodgkin's disease: Correlation of clinical characteristics with probabilities for negative lymphangiogram vs. negative laparotomy findings in patients with Stage I supradiaphragmatic presentations vs. those in patients with Stage II. <i>International Journal of Radiation Oncology Biology Physics</i> , 1998, 40, 377-386.	0.4	2
170	Dose dense CHOP: When more is not always better!. <i>Leukemia and Lymphoma</i> , 2007, 48, 845-846.	0.6	2
171	Pixantrone: a new agent for relapsed aggressive lymphomas. <i>Lancet Oncology</i> , The, 2012, 13, 654-656.	5.1	2
172	Check this checkpoint inhibitor in lymphoma. <i>Blood</i> , 2017, 130, 234-235.	0.6	2
173	The Baseline PET SUV Correlates Better with Clinical Outcome Than the Post-Therapy PET Scan in Previously Untreated Patients with Histologically Aggressive Non-Hodgkin Lymphoma (NHL). <i>Blood</i> , 2008, 112, 3588-3588.	0.6	2
174	A phase II trial of oral etoposide with mitoxantrone and ifosfamide/mesna consolidated with intravenous etoposide, methylprednisolone, high-dose arabinoside, and cisplatin as salvage therapy for relapsing and/or refractory lymphomas. <i>Investigational New Drugs</i> , 1994, 12, 217-222.	1.2	1
175	Salvage central lymphatic irradiation in follicular lymphomas following failure of chemotherapy: a feasibility study. <i>International Journal of Radiation Oncology Biology Physics</i> , 1999, 45, 1207-1212.	0.4	1
176	Molecular Response of Follicular Lymphoma to Cyclophosphamide, Doxorubicin, Vincristine, Prednisone C(H)OP or COP-Based Therapy as Measured by Polymerase Chain Reaction Evidence of Translocation (14;18)(q32;q21). <i>Cancer Journal (Sudbury, Mass)</i> , 2004, 10, 49-53.	1.0	1
177	Historical Perspective on the Treatment Challenges of Low-Grade Non-Hodgkin's Lymphoma. <i>Seminars in Hematology</i> , 2007, 44, S2-S6.	1.8	1
178	New developments in the field of diffuse large cell lymphoma. <i>Hematology</i> , 2012, 17, s98-s100.	0.7	1
179	Front-line immunochemotherapy for aggressive non-Hodgkin lymphoma using dose-dense rituximab, cyclophosphamide, doxorubicin, vincristine and prednisone plus granulocyte-macrophage colony stimulating factor and pegfilgrastim as support. <i>Leukemia and Lymphoma</i> , 2012, 53, 1929-1933.	0.6	1
180	A New Salvage Regimen for Aggressive Lymphomas Based on Gemcitabine, Rituximab, and Oxaliplatin Followed by Lenalidomide (GROC-Rev). <i>Clinical Lymphoma, Myeloma and Leukemia</i> , 2019, 19, 776-783.	0.2	1

#	ARTICLE	IF	CITATIONS
181	Managing Indolent Lymphomas in Relapse. Hematology American Society of Hematology Education Program, 2000, 2000, 166-179.	0.9	1
182	Open Editorial Office. Archives of Internal Medicine, 1978, 138, 1174.	4.3	0
183	Benign Fibrous Histiocytoma in Hodgkin's Disease. Cancer Investigation, 1984, 2, 347-350.	0.6	0
184	Frontline Management of Intermediate Grade Lymphomas at M. D. Anderson Hospital. Leukemia and Lymphoma, 1992, 7, 70-71.	0.6	0
185	Reply to I.E. Haines. Journal of Clinical Oncology, 2013, 31, 1798-1798.	0.8	0
186	Managing Indolent Lymphomas in Relapse. Hematology American Society of Hematology Education Program, 2000, 2000, 166-179.	0.9	0
187	T-Cell Rich B-Cell Lymphoma. American Journal of Surgical Pathology, 1997, 21, 499-500.	2.1	0
188	Rectal adenocarcinoma: proposal for a model based on pretreatment prognostic factors. Puerto Rico Health Sciences Journal, 2012, 31, 52-8.	0.2	0
189	Gastric MALT Lymphoma with Biclonal Gammopathy and Bone Marrow Involvement Mimicking Multiple Myeloma. Puerto Rico Health Sciences Journal, 2020, 39, 275-277.	0.2	0